Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen

BACKGROUND: Elderly patients with multiple myeloma (MM) are vulnerable to adverse events (AEs). This study evaluated adherence to chemotherapy and treatment outcomes in elderly patients treated with a frontline bortezomib (BTZ), melphalan, and prednisone (VMP) regimen and regimens without BTZ. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Hee-Jeong, Seo, Sang-Kyung, Baek, Dong Won, Park, Sung-Woo, Lee, Yoo-Jin, Sohn, Sang-Kyun, Lee, Ho-Sup, Lee, Won Sik, Lee, Ji Hyun, Kim, Sung Hyun, Moon, Joon-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yeungnam University College of Medicine 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784679/
https://www.ncbi.nlm.nih.gov/pubmed/31620574
http://dx.doi.org/10.12701/yujm.2018.35.1.76

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784679/
https://www.ncbi.nlm.nih.gov/pubmed/31620574
http://dx.doi.org/10.12701/yujm.2018.35.1.76

Ejemplares similares